#AS­CO19: Am­gen grows more con­fi­dent in KRAS G12C drug with a pos­i­tive snap­shot for lung can­cer — shares spike

CHICA­GO — Am­gen came to AS­CO as the leader in the race to de­vel­op the first tar­get­ed KRAS G12C drug for can­cer. And even as crit­ics have start­ed to take a shot at the field, they’re de­ter­mined to keep the lead straight through what’s shap­ing up as a hec­tic race among a grow­ing set of ri­vals.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER